Hudson Bay Capital Management
CBIO

Hudson Bay Capital Management’s Crescent Biopharma CBIO Stock Holding History

Hudson Bay Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-88,867
Closed -$1.63M – 1477
2026
Q1 		$1.63M Buy
+88,867
New +$1.02M 0.01% 802
2019
Q3 		– Sell
-3,000
Closed -$3.58M – 444
2019
Q2 		$3.58M Buy
3,000
+500
+20% +$598K 0.08% 218
2019
Q1 		$3.12M Sell
2,500
-1,000
-29% -$1.14M 0.04% 379
2018
Q4 		$3.31M Buy
3,500
+1,800
+106% +$2.17M 0.04% 394
2018
Q3 		$2.45M Buy
1,700
+500
+42% +$756K 0.03% 418
2018
Q2 		$1.94M Buy
1,200
+200
+20% +$344K 0.03% 515
2018
Q1 		$1.62M Sell
1,000
-400
-29% -$832K 0.03% 488
2017
Q4 		$2.35M Buy
1,400
+150
+12% +$198K 0.05% 289
2017
Q3 		$1.75M Buy
1,250
+448
+56% +$526K 0.04% 258
2017
Q2 		$894K Buy
+802
New +$663K 0.02% 425

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Hudson Bay Capital Management's CBIO Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Crescent Biopharma (CBIO) in Q2 2026, closing a stake of 88,867 shares — an estimated $1.63M sold.

Hudson Bay Capital Management first reported a position in CBIO in Q2 2017 and held it in 10 quarters. The position peaked at $3.58M in Q2 2019. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Crescent Biopharma position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 88,867 Crescent Biopharma shares in Q2 2026, an estimated $1.63M.
  • Hudson Bay Capital Management first reported a position in Crescent Biopharma in Q2 2017 and held it in 10 quarters.
  • Hudson Bay Capital Management's Crescent Biopharma position peaked at $3.58M in Q2 2019.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.